Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738055 | 0.86 | AKR1C3 (0.41) | AKR1C3 | |
| SCHEMBL25282888 | 0.86 | GPR84 (0.31) | NAMPTGPR84FFAR1FFAR4 | |
| SCHEMBL22983193 | 0.84 | ITGB3 (0.39) | AKR1C3 | |
| SCHEMBL26619704 | 0.84 | ITGB3 (0.39) | AKR1C3 | |
| SCHEMBL16528800 | 0.81 | AKR1C3 (0.40) | AKR1C3 | |
| SCHEMBL1069006 | 0.81 | AKR1C3 (0.40) | AKR1C3 | |
| SCHEMBL19276687 | 0.81 | CHRNB2 (0.42) | AKR1C3 | |
| SCHEMBL1840437 | 0.79 | ITGB3 (0.44) | NAMPTAKR1C3 | |
| SCHEMBL17474241 | 0.79 | SIGMAR1 (0.41) | NAMPT | |
| SCHEMBL1299334 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | NAMPT 3253/4885AKR1C3 119/4885CAMK2A 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.